Converting open heart surgery to
a transcatheter procedure.

Bringing new hope to millions
of patients

The Problem

Millions of heart failure patients are without a viable treatment

Severe functional mitral regurgitation (FMR) affects millions of patients. Due to high surgical risks, only a small percentage of patients undergo open-heart valve surgery. Nearly half of the remaining patients, who are treated with medication only, will die within two years.

VALFIX Solution

Converting open-heart valve surgery to a transcatheter procedure

VALFIX system offers a solution to the millions of patients currently without viable treatment.

VALFIX’s innovative and game-changing system allows cardiologists to perform transcatheter mitral valve repair procedures to alleviate heart failure symptoms, improve quality of life, and save lives.

Main Advantages

icon

Minimally Invasive Procedure

icon

Short
Procedure
Time

icon

Easy
Adoption By
Cardiologists

icon

Backed By Leading
Surgeons & Cardiologists

Why VALFIX is a game changer

Prof. Gregg W Stone, MD

Interventional Cardiologist, Mount Sinai New York

“What I like about the VALFIX device is that it serves as a standalone annuloplasty device, but it can serve also as a platform… it just provides a lot of flexibility of what the future may bring“

Dr. Thomas Modine, MD

Cardiac Surgeon, Bordeaux University

“The annuloplasty option is very, very important to achieve immediate and long-term outcomes which are sustainable over time. It is exactly what we need today to achieve and have on the shelf to offer to our patients.”

About Us

VALFIX was founded with a mission to heal hearts and save lives by experienced medical device entrepreneurs and a leading interventional cardiologist

VALFIX’s technology responds to the current large and clinically significant unmet need.

VALFIX’s proprietary technology has passed proof of concept and is moving forward to clinical trials.

News

01.02.2022

VALFIX Medical Inc. Appoints Former Abbott Ventures DVP,...

Read More

29.06.2021

VALFIX announces issuance of two new patents providing...

Read More

16.03.2021

VALFIX Medical announces patent granted in both Europe...

Read More

Contact Us


    Office:
    +972-73-374-4805
    Address:
    3 Menorat HaMa'or St., Tel-Aviv, Israel, 6744831
    Skip to content